Affordable Access

deepdyve-link
Publisher Website

Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets.

Authors
  • Chen, Kai1
  • Liu, Xinxin1
  • Liu, Weikang1
  • Wang, Feng2
  • Tian, Xiaodong1
  • Yang, Yinmo1
  • 1 Department of General Surgery, Peking University First Hospital, Beijing 100034, China. , (China)
  • 2 Department of Endoscopy Center, Peking University First Hospital, Beijing 100034, China. , (China)
Type
Published Article
Journal
Human Molecular Genetics
Publisher
Oxford University Press
Publication Date
May 19, 2022
Volume
31
Issue
10
Pages
1705–1719
Identifiers
DOI: 10.1093/hmg/ddab343
PMID: 34957503
Source
Medline
Language
English
License
Unknown

Abstract

The 5-year overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) is only 10%, partly owing to the lack of reliable diagnostic and prognostic biomarkers. The raw gene-cell matrix for single-cell RNA-seq (scRNA-seq) analysis was downloaded from the GSA database. We drew cell atlas for PDAC and normal pancreatic tissues. The inferCNV analysis was used to distinguish tumor cells from normal ductal cells. We identified differential expression genes (DEGs) by comparing tumor cells and normal ductal cells. The common DEGs were used to conduct prognostic and diagnostic model using univariate and multivariate Cox or logistic regression analysis. Four genes, MET, KLK10, PSMB9 and ITGB6, were utilized to create risk score formula to predict OS and to establish diagnostic model for PDAC. Finally, we drew an easy-to-use nomogram to predict 2-year and 3-year OSs. In conclusion, we developed and validated the prognostic and diagnostic model for PDAC based on scRNA-seq and bulk-seq datasets. © The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected]

Report this publication

Statistics

Seen <100 times